Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis (OCTIMS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02907281
Recruitment Status : Completed
First Posted : September 20, 2016
Last Update Posted : November 17, 2017
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:

This is a 3-year, pharmacologically non-interventional study to evaluate OCT as an outcome measure in patients with relapsing remitting multiple sclerosis (RRMS).

Approximately 350 RRMS patients, either untreated or treated with an approved MS disease-modifying therapy and approximately 70 reference subjects without ophthalmologic or neurologic disease are enrolled. No study medications are provided. Patients on disease-modifying therapy are treated according to the local prescribing information. For each MS patient and each reference subject, the study consists of Screening (up to 1 month), Baseline, and a 36-month longitudinal data collection phase. Eligibility will be confirmed during Screening.

Condition or disease Intervention/treatment
Multiple Sclerosis RRMS Other: Observational

Layout table for study information
Study Type : Observational
Actual Enrollment : 414 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: A 3-year, Multi-center Study to Evaluate Optical Coherence Tomography as an Outcome Measure in Patients With Multiple Sclerosis
Actual Study Start Date : May 29, 2012
Actual Primary Completion Date : July 24, 2017
Actual Study Completion Date : July 24, 2017

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
Multiple sclerosis patients
Multiple sclerosis patients
Other: Observational

Healthy volunteers
Healthy volunteers
Other: Observational

Primary Outcome Measures :
  1. Change in Retinal Nerve Fiber Layer Thickness (RNFL) [ Time Frame: 36 months ]
    evaluate change in RNFL thickness in relapsing remitting multiple sclerosis (RRMS) patients followed for up to 36 months compared to a group of reference subjects (without neurologic or ophthalmic disease) to determine whether the technology is sufficiently sensitive to disease and to change over time.

Secondary Outcome Measures :
  1. Correlation of change in macular volume with change in brain volume [ Time Frame: 36 months ]
    To evaluate the correlation of change in macular volume with change in brain volume as measured by MRI in RRMS patients followed for up to 36 months.

  2. Assess reproducibility of RNFL thickness on optical coherence tomography [ Time Frame: 4 weeks ]
    To evaluate short-team reproducibility of the RNFL thickness measure at study start by test/re-test estimation after a 4-week interval in RRMS patients and reference subjects (without neurologic or ophthalmic disease).

  3. Change in macular volume over 36 months [ Time Frame: 36 months ]
    To evaluate change in macular volume over 36 months in RRMS patients compared to a group of reference subjects (without neurologic or ophthalmic disease).

  4. Correlation of change in RNFL thickness with change in brain volume [ Time Frame: 36 months ]
    To evaluate the correlation of change in RNFL thickness with change in brain volume as measured by magnetic resonance imaging (MRI) in RRMS patients followed for up to 36 months.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Multiple Sclerosis patients and healthy volunteers

Multiple sclerosis patients

  • A diagnosis of MS as defined by the 2005 revision to the McDonald criteria with a relapsing-remitting course
  • MS disease duration of more than one year (from diagnosis of MS) before study entry

Healthy volunteers

- Matched to MS patients based on age, gender, ethnicity and visual refraction

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02907281

Layout table for location information
United States, California
Novartis Investigative Site
San Francisco, California, United States, 94143-0359
Novartis Investigative Site
Torrance, California, United States, 90509-2004
United States, Iowa
Novartis Investigative Site
Iowa City, Iowa, United States, 52242
United States, Maryland
Novartis Investigative Site
Baltimore, Maryland, United States, 21287
United States, Pennsylvania
Novartis Investigative Site
Philadelphia, Pennsylvania, United States, 19104-4283
Australia, New South Wales
Novartis Investigative Site
Camperdown, New South Wales, Australia, 2050
Australia, Victoria
Novartis Investigative Site
Parkville,, Victoria, Australia, 3065
Canada, Alberta
Novartis Investigative Site
Calgary, Alberta, Canada, T2N 4Z1
Canada, Quebec
Novartis Investigative Site
Greenfield Park, Quebec, Canada, J4V 2J2
Novartis Investigative Site
Praha 2, Czechia, 128 08
Novartis Investigative Site
Copenhagen, Denmark, DK-2100
Novartis Investigative Site
Berlin, Germany, 10117
Novartis Investigative Site
Magdeburg, Germany, 39120
Novartis Investigative Site
Cagliari, CA, Italy, 09126
Novartis Investigative Site
Milano, MI, Italy, 20132
Novartis Investigative Site
Bari, Italy, 70124
Novartis Investigative Site
Genova, Italy, 16132
Novartis Investigative Site
Montichiari, Italy, 25018
Novartis Investigative Site
Padova, Italy, 35128
Novartis Investigative Site
Roma, Italy, 189
Novartis Investigative Site
Amsterdam, Netherlands, 1081
Novartis Investigative Site
Lodz, Lódzkie, Poland, 90-153
Novartis Investigative Site
Barcelona, Catalunya, Spain, 08035
Novartis Investigative Site
Barcelona, Cataluña, Spain, 8036
Novartis Investigative Site
Valencia, Comunidad Valenciana, Spain, 46026
Novartis Investigative Site
Madrid, Spain, 28040
Novartis Investigative Site
Zürich, Switzerland, 8091
United Kingdom
Novartis Investigative Site
London, United Kingdom, EC1V 2PD
Sponsors and Collaborators
Novartis Pharmaceuticals
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals Identifier: NCT02907281    
Other Study ID Numbers: CFTY720D2319
2011-001437-16 ( EudraCT Number )
First Posted: September 20, 2016    Key Record Dates
Last Update Posted: November 17, 2017
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Multiple sclerosis,
Optical coherence tomography
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases